{"id":55710,"date":"2023-04-12T00:03:08","date_gmt":"2023-04-11T22:03:08","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/vasocorp-announces-completion-of-phase-i-clinical-trial-on-nerve-support-formula-neuropaway-as-a-dietary-supplement-for-occasional-nerve-discomfort\/"},"modified":"2023-04-12T00:03:08","modified_gmt":"2023-04-11T22:03:08","slug":"vasocorp-announces-completion-of-phase-i-clinical-trial-on-nerve-support-formula-neuropaway-as-a-dietary-supplement-for-occasional-nerve-discomfort","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/vasocorp-announces-completion-of-phase-i-clinical-trial-on-nerve-support-formula-neuropaway-as-a-dietary-supplement-for-occasional-nerve-discomfort\/","title":{"rendered":"VasoCorp Announces Completion of Phase I Clinical Trial on Nerve Support Formula “NeuropAWAY\u00ae” as a Dietary Supplement for Occasional Nerve Discomfort"},"content":{"rendered":"
\n

ATLANTA–(BUSINESS WIRE)–VasoCorp, a Georgia for-profit corporation, on a mission to change the standard of care for those suffering from neuropathic discomfort by proving the efficacy of a dietary supplement formula, announced today the results from their Phase I clinical trial<\/a>. VasoCorp is making life better for those in need of an alternative solution to the prescription drugs that are now used to deal with this condition.<\/p>\n

<\/a><\/p>\n

\nThe trial was authored by William Cross, President and Founder of VasoCorp, and Dr. Shalini` Srivastava, Director, Vedic Life Sciences, Mumbai, India. Mr. Cross has a record of research on innovative ideas and basic science discoveries. In 2017, Mr. Cross was awarded Young Entrepreneur of the Year by the U.S. Small Business Administration’s Georgia District Office<\/a> who acknowledge that his “efforts…have helped thousands of people ease their debilitating pain.”<\/p>\n

\nThe study was conducted under supervision of Dr. Shalini` Srivastava, Vedic Life Sciences, Mumbai, India. The primary objective of the study was to evaluate the effects of a dietary Nerve Support Formula on diabetic neuropathic pain. The results of the study were significant and could have profound, life-changing impacts on the health and wellness of those suffering from nerve discomfort.<\/p>\n

\nThe trial was funded by VasoCorp. “Our funding strategy is laser-focused on addressing areas of unmet need for maintaining nerve health in the aging population. The study results have huge potential to dial back the focus on prescription drugs, providing new options and a better quality of life,” said Mr. Cross, VasoCorp Founder and President.<\/p>\n

\nMr. Cross has recently updated VasoCorp’s portfolio of products with similar novel formulas that support Kidney and Eye health.<\/p>\n

\nAbout VasoCorp:<\/b> VasoCorp is a vitamin supplement company founded in 2016. VasoCorp\u2019s NeuropAWAY\u00ae Brand products are focused on the diabetes health market, the aging population, and the health and wellness market. VasoCorp\u2019s patented and patent pending formulas offer a new approach to managing occasional nerve aches, and an alternative to opioids.<\/p>\n

\nAbout Vedic Life Sciences: <\/b>Vedic Lifesciences is a contract research organization (CRO), that has completed more than 400 clinical and preclinical studies in compliance with international regulations. Vedic Lifesciences is among the few GCP-compliant CROs that are fully aligned with the FDA and FTC standards for human studies.<\/p>\n

Contacts<\/b> <\/p>\n

\nBill Cross
\n
770-756-3137
\n
bill@vasocorp.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

ATLANTA–(BUSINESS WIRE)–VasoCorp, a Georgia for-profit corporation, on a mission to change the standard of care for those suffering from neuropathic discomfort by proving the efficacy of a dietary supplement formula, announced today the results from their Phase I clinical trial. VasoCorp is making life better for those in need of an alternative solution to the … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-55710","6":"format-standard","7":"category-industry"},"yoast_head":"\nVasoCorp Announces Completion of Phase I Clinical Trial on Nerve Support Formula "NeuropAWAY\u00ae" as a Dietary Supplement for Occasional Nerve Discomfort - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/vasocorp-announces-completion-of-phase-i-clinical-trial-on-nerve-support-formula-neuropaway-as-a-dietary-supplement-for-occasional-nerve-discomfort\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"VasoCorp Announces Completion of Phase I Clinical Trial on Nerve Support Formula "NeuropAWAY\u00ae" as a Dietary Supplement for Occasional Nerve Discomfort - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"ATLANTA–(BUSINESS WIRE)–VasoCorp, a Georgia for-profit corporation, on a mission to change the standard of care for those suffering from neuropathic discomfort by proving the efficacy of a dietary supplement formula, announced today the results from their Phase I clinical trial. VasoCorp is making life better for those in need of an alternative solution to the ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/vasocorp-announces-completion-of-phase-i-clinical-trial-on-nerve-support-formula-neuropaway-as-a-dietary-supplement-for-occasional-nerve-discomfort\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-11T22:03:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230411005957\/en\/1761391\/21\/Neuropaway_Logo1.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vasocorp-announces-completion-of-phase-i-clinical-trial-on-nerve-support-formula-neuropaway-as-a-dietary-supplement-for-occasional-nerve-discomfort\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vasocorp-announces-completion-of-phase-i-clinical-trial-on-nerve-support-formula-neuropaway-as-a-dietary-supplement-for-occasional-nerve-discomfort\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"VasoCorp Announces Completion of Phase I Clinical Trial on Nerve Support Formula “NeuropAWAY\u00ae” as a Dietary Supplement for Occasional Nerve Discomfort\",\"datePublished\":\"2023-04-11T22:03:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vasocorp-announces-completion-of-phase-i-clinical-trial-on-nerve-support-formula-neuropaway-as-a-dietary-supplement-for-occasional-nerve-discomfort\\\/\"},\"wordCount\":402,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vasocorp-announces-completion-of-phase-i-clinical-trial-on-nerve-support-formula-neuropaway-as-a-dietary-supplement-for-occasional-nerve-discomfort\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230411005957\\\/en\\\/1761391\\\/21\\\/Neuropaway_Logo1.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vasocorp-announces-completion-of-phase-i-clinical-trial-on-nerve-support-formula-neuropaway-as-a-dietary-supplement-for-occasional-nerve-discomfort\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vasocorp-announces-completion-of-phase-i-clinical-trial-on-nerve-support-formula-neuropaway-as-a-dietary-supplement-for-occasional-nerve-discomfort\\\/\",\"name\":\"VasoCorp Announces Completion of Phase I Clinical Trial on Nerve Support Formula \\\"NeuropAWAY\u00ae\\\" as a Dietary Supplement for Occasional Nerve Discomfort - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vasocorp-announces-completion-of-phase-i-clinical-trial-on-nerve-support-formula-neuropaway-as-a-dietary-supplement-for-occasional-nerve-discomfort\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vasocorp-announces-completion-of-phase-i-clinical-trial-on-nerve-support-formula-neuropaway-as-a-dietary-supplement-for-occasional-nerve-discomfort\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230411005957\\\/en\\\/1761391\\\/21\\\/Neuropaway_Logo1.jpg\",\"datePublished\":\"2023-04-11T22:03:08+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vasocorp-announces-completion-of-phase-i-clinical-trial-on-nerve-support-formula-neuropaway-as-a-dietary-supplement-for-occasional-nerve-discomfort\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vasocorp-announces-completion-of-phase-i-clinical-trial-on-nerve-support-formula-neuropaway-as-a-dietary-supplement-for-occasional-nerve-discomfort\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vasocorp-announces-completion-of-phase-i-clinical-trial-on-nerve-support-formula-neuropaway-as-a-dietary-supplement-for-occasional-nerve-discomfort\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230411005957\\\/en\\\/1761391\\\/21\\\/Neuropaway_Logo1.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230411005957\\\/en\\\/1761391\\\/21\\\/Neuropaway_Logo1.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vasocorp-announces-completion-of-phase-i-clinical-trial-on-nerve-support-formula-neuropaway-as-a-dietary-supplement-for-occasional-nerve-discomfort\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"VasoCorp Announces Completion of Phase I Clinical Trial on Nerve Support Formula “NeuropAWAY\u00ae” as a Dietary Supplement for Occasional Nerve Discomfort\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"VasoCorp Announces Completion of Phase I Clinical Trial on Nerve Support Formula \"NeuropAWAY\u00ae\" as a Dietary Supplement for Occasional Nerve Discomfort - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/vasocorp-announces-completion-of-phase-i-clinical-trial-on-nerve-support-formula-neuropaway-as-a-dietary-supplement-for-occasional-nerve-discomfort\/","og_locale":"en_US","og_type":"article","og_title":"VasoCorp Announces Completion of Phase I Clinical Trial on Nerve Support Formula \"NeuropAWAY\u00ae\" as a Dietary Supplement for Occasional Nerve Discomfort - Pharma Trend","og_description":"ATLANTA–(BUSINESS WIRE)–VasoCorp, a Georgia for-profit corporation, on a mission to change the standard of care for those suffering from neuropathic discomfort by proving the efficacy of a dietary supplement formula, announced today the results from their Phase I clinical trial. VasoCorp is making life better for those in need of an alternative solution to the ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/vasocorp-announces-completion-of-phase-i-clinical-trial-on-nerve-support-formula-neuropaway-as-a-dietary-supplement-for-occasional-nerve-discomfort\/","og_site_name":"Pharma Trend","article_published_time":"2023-04-11T22:03:08+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230411005957\/en\/1761391\/21\/Neuropaway_Logo1.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/vasocorp-announces-completion-of-phase-i-clinical-trial-on-nerve-support-formula-neuropaway-as-a-dietary-supplement-for-occasional-nerve-discomfort\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/vasocorp-announces-completion-of-phase-i-clinical-trial-on-nerve-support-formula-neuropaway-as-a-dietary-supplement-for-occasional-nerve-discomfort\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"VasoCorp Announces Completion of Phase I Clinical Trial on Nerve Support Formula “NeuropAWAY\u00ae” as a Dietary Supplement for Occasional Nerve Discomfort","datePublished":"2023-04-11T22:03:08+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/vasocorp-announces-completion-of-phase-i-clinical-trial-on-nerve-support-formula-neuropaway-as-a-dietary-supplement-for-occasional-nerve-discomfort\/"},"wordCount":402,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/vasocorp-announces-completion-of-phase-i-clinical-trial-on-nerve-support-formula-neuropaway-as-a-dietary-supplement-for-occasional-nerve-discomfort\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230411005957\/en\/1761391\/21\/Neuropaway_Logo1.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/vasocorp-announces-completion-of-phase-i-clinical-trial-on-nerve-support-formula-neuropaway-as-a-dietary-supplement-for-occasional-nerve-discomfort\/","url":"https:\/\/pharma-trend.com\/en\/vasocorp-announces-completion-of-phase-i-clinical-trial-on-nerve-support-formula-neuropaway-as-a-dietary-supplement-for-occasional-nerve-discomfort\/","name":"VasoCorp Announces Completion of Phase I Clinical Trial on Nerve Support Formula \"NeuropAWAY\u00ae\" as a Dietary Supplement for Occasional Nerve Discomfort - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/vasocorp-announces-completion-of-phase-i-clinical-trial-on-nerve-support-formula-neuropaway-as-a-dietary-supplement-for-occasional-nerve-discomfort\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/vasocorp-announces-completion-of-phase-i-clinical-trial-on-nerve-support-formula-neuropaway-as-a-dietary-supplement-for-occasional-nerve-discomfort\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230411005957\/en\/1761391\/21\/Neuropaway_Logo1.jpg","datePublished":"2023-04-11T22:03:08+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/vasocorp-announces-completion-of-phase-i-clinical-trial-on-nerve-support-formula-neuropaway-as-a-dietary-supplement-for-occasional-nerve-discomfort\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/vasocorp-announces-completion-of-phase-i-clinical-trial-on-nerve-support-formula-neuropaway-as-a-dietary-supplement-for-occasional-nerve-discomfort\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/vasocorp-announces-completion-of-phase-i-clinical-trial-on-nerve-support-formula-neuropaway-as-a-dietary-supplement-for-occasional-nerve-discomfort\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230411005957\/en\/1761391\/21\/Neuropaway_Logo1.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230411005957\/en\/1761391\/21\/Neuropaway_Logo1.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/vasocorp-announces-completion-of-phase-i-clinical-trial-on-nerve-support-formula-neuropaway-as-a-dietary-supplement-for-occasional-nerve-discomfort\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"VasoCorp Announces Completion of Phase I Clinical Trial on Nerve Support Formula “NeuropAWAY\u00ae” as a Dietary Supplement for Occasional Nerve Discomfort"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55710","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=55710"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55710\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=55710"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=55710"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=55710"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}